James Stambaugh - Intersect ENT Vice President of Clinical and Reimbursement
| XENTDelisted Stock | USD 28.24 0.00 0.00% |
President
Mr. James Stambaugh is Vice President of Clinical and Reimbursement at Intersect ENT, Inc. Prior to Intersect ENT, he served as Director of Clinical Operations at Guidant Vascular Intervention division, responsible for conducting clinical studies for coronary embolic protection, stents, and drugeluting stents. During his 11 years at Guidant, he held various positions within the preclinical, clinical and regulatory environment. His combined 18 years of experience in medical device, pharmaceutical, and combination product development includes design and management of human clinical trials, conduct of invivo and invitro preclinical experiments, and experience with design controls, design validation, and risk analysis since 2006.
| Age | 45 |
| Tenure | 18 years |
| Professional Marks | MBA |
| Phone | 650 641-2100 |
| Web | www.intersectent.com |
Intersect ENT Management Efficiency
The company has return on total asset (ROA) of (17.82) % which means that it has lost $17.82 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (181.73) %, meaning that it created substantial loss on money invested by shareholders. Intersect ENT's management efficiency ratios could be used to measure how well Intersect ENT manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 129.11 M in liabilities with Debt to Equity (D/E) ratio of 7.96, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Intersect ENT has a current ratio of 2.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Intersect ENT until it has trouble settling it off, either with new capital or with free cash flow. So, Intersect ENT's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Intersect ENT sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Intersect to invest in growth at high rates of return. When we think about Intersect ENT's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Steven Creviston | Qorvo Inc | 60 | |
| Greg Henderson | Analog Devices | 49 | |
| Margaret Seif | Analog Devices | 56 | |
| Joseph Hassett | Analog Devices | 66 | |
| Yusuf Jamal | Analog Devices | 40 | |
| Charles Schmaderer | AMCON Distributing | 55 | |
| Eric Hinkefent | AMCON Distributing | 53 | |
| Steven Pietkiewicz | Analog Devices | 58 | |
| William Matson | Analog Devices | 54 | |
| Chitung Liu | United Microelectronics | 58 | |
| Prashanth MahendraRajah | Analog Devices | 54 | |
| Paul Fego | Qorvo Inc | 66 | |
| Rick Hess | Analog Devices | 61 | |
| James Klein | Qorvo Inc | 52 | |
| Andrew Plummer | AMCON Distributing | 50 | |
| Jean Philibert | Analog Devices | 56 | |
| Thomas Wessel | Analog Devices | 47 | |
| Martin Cotter | Analog Devices | 59 | |
| Primit Parikh | Transphorm Technology | 52 | |
Management Performance
| Return On Equity | -181.73 | |||
| Return On Asset | -17.82 |
Intersect ENT Leadership Team
Elected by the shareholders, the Intersect ENT's board of directors comprises two types of representatives: Intersect ENT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intersect. The board's role is to monitor Intersect ENT's management team and ensure that shareholders' interests are well served. Intersect ENT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intersect ENT's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lisa Earnhardt, CEO and President and Director | ||
| William Vernon, Director | ||
| Christine Kowalski, COO | ||
| James Stambaugh, Vice President of Clinical and Reimbursement | ||
| Richard Kaufman, COO and Sr. VP | ||
| Casey Tansey, Independent Director | ||
| David Lehman, General Counsel | ||
| Drake Parker, Advisor – Strategic Initiatives | ||
| Amy Wolbeck, Vice President of Regulatory Affairs and Quality | ||
| Robert Binney, Chief Commercial Officer | ||
| Susan Stimson, Chief Strategy Officer | ||
| Dana Mead, Independent Director | ||
| Gwen Carscadden, Chief People Officer | ||
| Frederic Moll, Independent Director | ||
| Kieran Gallahue, Lead Director | ||
| Jeryl Hilleman, CFO | ||
| Thomas West, President CEO, Director | ||
| Cynthia Lucchese, Independent Director | ||
| Chas McKhann, Chief Commercial Officer | ||
| Teresa Kline, Director |
Intersect Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intersect ENT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -181.73 | |||
| Return On Asset | -17.82 | |||
| Profit Margin | (85.02) % | |||
| Operating Margin | (54.81) % | |||
| Current Valuation | 961.95 M | |||
| Shares Outstanding | 33.46 M | |||
| Shares Owned By Insiders | 6.80 % | |||
| Shares Owned By Institutions | 92.15 % | |||
| Number Of Shares Shorted | 1.44 M | |||
| Price To Earning | (42.68) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Other Consideration for investing in Intersect Stock
If you are still planning to invest in Intersect ENT check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intersect ENT's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Stocks Directory Find actively traded stocks across global markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |